申请人:Taiho Pharmaceutical Co., Ltd
公开号:US20200405697A1
公开(公告)日:2020-12-31
The present invention provides a method of enhancing an antitumor effect by a compound strongly inhibiting ribonucleotide reductase (RNR) or a salt thereof.
A combination formulation involving combined administration of a sulfonamide compound represented by Formula (I) [In the formula, X
1
represents an oxygen atom or the like; X
2
represents an oxygen atom; X
3
represents —NH—; X
4
represents a hydrogen atom or the like; R
1
represents —C(R
11
) (R
12
)— or the like; R
11
and R
12
are the same or different and each represents a hydrogen atom or the like; R
2
represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R
3
represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R
4
represents a hydrogen atom or the like] or a salt thereof, having RNR inhibitory activity, and other antitumor agent(s).